Source: ThinkstockJanuary 8, 2018: The S&P 500 closed up 0.2% at 2,747.45. The DJIA closedrelatively flat at 25,278.49. Separately, the Nasdaq was up 0.3% at 7,157.39.
Although Monday was a relatively mixed day for the markets, all three of the major exchanges hit all-time highs yet again. This is only the fifth trading day of the New Year and markets have been setting records on practically....More>>>
GOP Proposes Radical Change to 401(k) System
U.S. Stocks Should Terrify Janet Yellen: Billionaire Investor
Insurers Get 180 Days of SIFI Designation Relief
Advisors: Your valuable input is needed for our research. What factors weigh in on your use of ETFs in your business and how do you utilize them in your clients’ portfolios? Please take a few moments to participate....More>>>
Allergan (NYSE:AGN) is one of the many biotech stocks that has been beaten down in the last one and a half year. In this article I will indicate 4 reasons why I think the company and the stock can perform well in the future.
Reason #1: Diversified sources of revenue and rich pipeline
One of the characteristics that I like in Allergan is its rich portfolio of drugs. As we can see....More>>>
AT&T’s (NYSE:T) roll-out of the DirecTV Now service has been greeted by enthusiasm by some (me) and skepticism by others. The later camp notes that margins, at least on the introductory pricing, are likely to be slim and may cannibalize the company’s traditional DirecTV product offering.
In my mind, the DirecTV Now product was a forward-looking master stroke that begins....More>>>
bluebird bio, (NASDAQ:BLUE) is one of the oncology immunotherapy stocks I mentioned recently as worth a good look, (article titled ‘Immunotherapy Over Reaction’, a basic primer to the immunotherapy subsector and its ETF). BLUE is also a recent Cramer pick. Immunotherapy stocks have been hit hard over the summer but BLUE is a relatively highly valued genetic specialist, with some interesting....More>>>
Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed “Aphinity.”
Image source: Getty Images.
In Roche’s trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy,....More>>>
One of the smaller details of Trumpcare, the redacted version of Obamacare, is the elimination of a tax imposed on manufacturers of medical devices. While the fate of pre-existing conditions has been hogging the spotlight in recent days, this particular tax and its future could have an impact on companies like Ventripoint Diagnostics (OTCMKTS: VPTDF TSE:VPT), and other small cap biotech....More>>>
Healthcare spending is on track to make up nearly 20% of U.S. GDP by 2025, according to the U.S. Centers for Medicare & Medicaid Services (CMS).
That’s one of the reasons we expect the biotech stock we’re showing you today to double in price by 2020.
Another catalyst for this top biotech stock is the aging baby boomer generation. There are currently 76.5 million....More>>>
Starting with a simple tweet on September 21st, 2015, Hillary Clinton has been pummeling Biotech stocks since her Presidential Campaign first began. In fact, Clinton has caused dramatic drops in the iShares Nasdaq Biotechnology ETF (IBB) at least three times in the past 14 months. The thought of Clinton winning the presidency, and the corresponding assault on the Biotech sector,....More>>>
Its been said of biotech that its the wild west of the investment world. There may be gold in the hills but you better have a good map and a keen eye to find it. One such company that is shimmering of late is Ventripoint Diagnostics (OTC: VPTDF), the Toronto, Ontario based developer of medical devices. With its new cardiac imaging device, the VMS Plus , Ventripoint is changing the way....More>>>